Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | PTPRC | P08575 | 1/20 | 0.44 |
| ▸ | S100A4 | P26447 | 1/20 | 0.44 |
| ▸ | HSPB1 | P04792 | 3/20 | 0.42 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31554518 | 1.00 | ALDH1A1 (0.57) | ALDH1A1HIF1ATSHRLMNAKMT2A | |
| SCHEMBL28027920 | 0.83 | ALDH1A1 (0.62) | ALDH1A1HIF1ATSHRLMNAKMT2A | |
| SCHEMBL11822059 | 0.80 | TSHR (0.52) | ALDH1A1HIF1ATSHRLMNATDP1 | |
| SCHEMBL29379039 | 0.80 | ALDH1A1 (0.69) | ALDH1A1HIF1ATSHRLMNAKMT2A | |
| SCHEMBL85604 | 0.80 | ALDH1A1 (0.69) | ALDH1A1HIF1ATSHRLMNAKMT2A | |
| SCHEMBL28252591 | 0.80 | ALDH1A1 (0.69) | ALDH1A1HIF1ATSHRLMNAKMT2A | |
| Hydrochloric Acid SCHEMBL30306150 | 0.78 | ALDH1A1 (0.67) | ALDH1A1HIF1ATSHRLMNAKMT2A | |
| SCHEMBL31474855 | 0.77 | ALDH1A1 (0.70) | ALDH1A1HIF1ATSHRLMNAKMT2A | |
| SCHEMBL3029469 | 0.77 | ALDH1A1 (0.59) | ALDH1A1HIF1ATSHRLMNAKMT2A | |
| SCHEMBL1637306 | 0.77 | ALDH1A1 (0.70) | ALDH1A1HIF1ATSHRLMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104072480-B | Quinolines and its preparation method and application | 沈阳药科大学 | 2016-12-28 | — | — | CN | disclosed |
| CN-104119317-B | Quinolines containing 1,2,3-triazole and its preparation method and application | 沈阳药科大学 | 2016-08-17 | — | — | CN | disclosed |
| CN-105017217-A | Pyrazolone-containing quinoline compound and preparation method and application thereof | UNIV SHENYANG PHARMACEUTICAL | 2015-11-04 | — | — | CN | disclosed |
| CN-104119317-A | Quinoline compound containing 1,2,3-triazole as well as preparation method and application thereof | UNIV SHENYANG PHARMACEUTICAL | 2014-10-29 | — | — | CN | disclosed |
| CN-104072480-A | Quinoline type compounds and preparing method and applications thereof | UNIV SHENYANG PHARMACEUTICAL | 2014-10-01 | — | — | CN | disclosed |
| CN-103965107-A | 2-aryl-substituted quinoline compounds and application thereof | UNIV SHENYANG PHARMACEUTICAL | 2014-08-06 | — | — | CN | disclosed |
| CN-102643268-B | Quinoline and cinnoline compound and application thereof | UNIV SHENYANG PHARMACEUTICAL | 2014-05-21 | — | — | CN | disclosed |
| CN-103709145-A | Quinolines compound containing hexahydropyrimidone as well as preparation method and application thereof | UNIV SHENYANG PHARMACEUTICAL | 2014-04-09 | — | — | CN | disclosed |
| CN-101812003-B | Small-angle inverted V-shaped fluorine-containing lateral chain ferroelectric liquid crystal compound and synthesis method thereof | UNIV BEIHANG | 2013-02-20 | — | — | CN | disclosed |
| CN-102643268-A | Quinoline and cinnoline compound and application thereof | UNIV SHENYANG PHARMACEUTICAL | 2012-08-22 | — | — | CN | disclosed |
| US-20060264481-A1 | Therapeutic modulation of PPARgamma activity | AMGEN INC. (US) | 2006-11-23 | — | — | US | disclosed |
| EP-1722789-A2 | THERAPEUTIC MODULATION OF PPAR (GAMMA) ACTIVITY | Amgen Inc. (US) | 2006-11-22 | — | — | EP | disclosed |
| US-7041691-B1 | Compounds for the modulation of PPARγ activity | AMGEN INC. (US) | 2006-05-09 | — | — | US | disclosed |
| US-20050250820-A1 | Therapeutic modulation of PPARgamma activity | AMGEN INC. (US) | 2005-11-10 | — | — | US | disclosed |
| WO-2005086904-A2 | THERAPEUTIC MODULATION OF PPAR (GAMMA) ACTIVITY | AMGEN INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| US-20040248882-A1 | Noninsulin dependent diabetes, obesity, hypercholesterolemia, inflammatory disorders; reduced side effects; such as 5-(4-acetylbenzenesulfonamido-2-fluorophenoxy)-3-chloropyridine | TULARIK INC. | 2004-12-09 | — | — | US | disclosed |
| US-6770648-B2 | ANTIDIABETIC AGENTS | TULARIK INC. | 2004-08-03 | — | — | US | disclosed |
| US-20030139390-A1 | Compounds for the modulation of PPARgamma activity | TULARIK INC. | 2003-07-24 | — | — | US | disclosed |
| EP-1192137-A1 | COMPOUNDS FOR THE MODULATION OF PPAR$g(g) ACTIVITY | Tularik Inc. (US) | 2002-04-03 | — | — | EP | disclosed |
| WO-2001000579-A1 | COMPOUNDS FOR THE MODULATION OF PPARη ACTIVITY | TULARIK INC. (US) | 2001-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250820-A1 | Therapeutic modulation of PPARgamma activity | PPARG, PPARA, PPARD | ALDH1A1 1672/4885HIF1A 1761/4885TSHR 653/4885 |
| US-20060264481-A1 | Therapeutic modulation of PPARgamma activity | PPARG, PPARA, PPARD | ALDH1A1 1672/4885HIF1A 1761/4885TSHR 653/4885 |
| US-20030139390-A1 | Compounds for the modulation of PPARgamma activity | PPARG, PPARA, PPARD | ALDH1A1 1831/4885HIF1A 2857/4885TSHR 645/4885 |
| US-20040248882-A1 | Noninsulin dependent diabetes, obesity, hypercholesterolemia, inflammatory disorders; reduced side effects; such as 5-(4-acetylbenzenesulfonamido-2-fluorophenoxy)-3-chloropyridine | PPARD, PPARG, PPARA | ALDH1A1 1482/4885HIF1A 2784/4885TSHR 2689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.